London’s FTSE 100 was muted on Thursday after its longest gaining streak since 2017, with a slate of disappointing earnings ...

Semaglutide — known by brand names Ozempic and Wegovy — works in the brain to impact satiety. Over the past two years, the ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has ...

With more than 40% of U.S. adults having been diagnosed with liver disease, Virginia Commonwealth University (VCU) research suggests that there might be a way to treat fatty liver disease.

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...